Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
about
Sequential versus combination chemotherapy for advanced colorectal cancerSecond-line chemotherapy in advanced and metastatic CRCPhase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignanciesA prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapySurvey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancerEvidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Advances in drug delivery system for platinum agents based combination therapyReview of systemic therapies for locally advanced and metastatic rectal cancerRegulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damageForced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cellsSatraplatin: leading the new generation of oral platinum agentsSecond-line systemic therapy for metastatic colorectal cancer.A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.The role of primary tumour resection in patients with stage IV colorectal cancer.Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerPhase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer.A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studySurgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional studyComplete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapyPredicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradationInhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDI(QQ))]Cl.Cost implications of new treatments for advanced colorectal cancer.Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.Primary site resection is superior for incurable metastatic colorectal cancer.Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesA phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cellsThymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancersUsing Drosophila melanogaster to identify chemotherapy toxicity genes.Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.Personalized colon cancer care in 2010.A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in micePhase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.
P2860
Q24234461-BE6B46F9-C7B0-4646-BD94-D542E62A35AAQ24241235-C2D53250-CDDD-4951-A802-AF70383A390FQ24644011-50C36187-7A66-4F99-B085-9E5A1419D86AQ24811929-D8F97207-2214-4DFA-845F-1BA77545D260Q24815800-BF00B64D-FCBE-47C3-9A98-D51286C553C1Q26752747-7EEF6725-4333-488F-85B7-031AB4B2F3A5Q26771390-5FA1C326-64AC-4ABB-B9EC-A97486A2B246Q27021105-A0439083-A29B-4D0A-970E-A0EA2016ECC8Q28301157-C18A4987-C225-464A-AFD9-640E75DDA981Q28659746-D7D66EFA-D9A8-4260-B6D0-37F7393584CBQ28972468-7F13A9C2-7EE2-4029-A84A-2071DAD80C80Q30238760-F7BB8FE2-892A-471C-BB8F-3E0FB86F7E9CQ31080865-31E415FC-CBE3-47F7-BFB4-CAEDEEF2FE2FQ33284711-E3288148-8606-4E4A-A1C4-662D2D8583BFQ33378863-471E4F52-E92A-4707-A94A-69B19B13FAB1Q33384357-C83A0682-7780-4F6E-93DC-8CB0CCECFF4AQ33387187-B51519FF-2AA8-4EA4-9FD2-2349501E8947Q33387297-26AE33F2-4262-400C-B8DF-5A67CAA9EB83Q33390957-AA8973B9-27E5-475D-9258-ECD31BED1439Q33622783-BEE5846E-5616-4E55-ADEA-BE0A3D6F3790Q33638615-1A0053E3-59C9-444B-8379-8A3092A373A2Q33729092-3921C8D2-0ECB-4D11-8835-8E50C1509E94Q33746897-C5C36F64-3DF7-46A5-B99C-4ADACD8759B6Q33826355-E0AA6F47-1809-4CDE-9B4A-E508B280B109Q33845577-46648F1C-F442-4FB6-B21F-887A183289B9Q33847443-620C495C-B30D-4B8E-872F-757C4CC529FDQ33874203-9E28C762-7D35-409F-AA42-1B881A817B1EQ33931049-711BBF9B-9441-4B49-A248-AD6832AC6D9AQ34018266-EB90A364-2EC4-401A-AFE1-A275315C02EFQ34023788-3A57B1A2-4770-45E0-9B76-7A84C54A1696Q34099365-783D2836-824F-4E03-B054-EA1B6F2CB69BQ34113977-BED21797-DCF8-426F-9D8F-38F9067ED410Q34214957-A58903B2-97C7-4EAD-9DFC-FC6DDBD7748FQ34242959-7D823FF4-7DFB-44E0-8286-91A588CFBA2DQ34335452-0F1553E3-C906-4BCA-9207-EF683A16C799Q34606724-AD2D71F9-75CC-47F9-B954-A713D103DFF8Q34731381-DB29A33E-E2D6-48FF-83E1-58367F9F64D8Q34910416-3EF988AE-6BB5-4D0E-8367-188697A6EFEBQ35019148-F4F78C3E-A70C-4FFB-80C9-2EF436D7B691Q35025710-62906640-1D4A-4801-BC05-446CC99C26CC
P2860
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Superiority of oxaliplatin and ...... results of a phase III trial.
@en
Superiority of oxaliplatin and ...... results of a phase III trial.
@nl
type
label
Superiority of oxaliplatin and ...... results of a phase III trial.
@en
Superiority of oxaliplatin and ...... results of a phase III trial.
@nl
prefLabel
Superiority of oxaliplatin and ...... results of a phase III trial.
@en
Superiority of oxaliplatin and ...... results of a phase III trial.
@nl
P2093
P921
P356
P1476
Superiority of oxaliplatin and ...... results of a phase III trial.
@en
P2093
Amit M Oza
Brent G Burger
Carlos A Garay
Daniel G Haller
John L Marshall
Jordan D Berlin
Lowell L Hart
Mace L Rothenberg
Nathalie Le Bail
Ramesh K Ramanathan
P304
P356
10.1200/JCO.2003.11.126
P407
P577
2003-06-01T00:00:00Z